TriSalus announces journal publication of PEDD study

TriSalus Life Sciences (TLSI) announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery technology used in trans-arterial chemoembolization and radioembolization procedures. The study, titled “Clinical Outcomes of Pressure-Enabled Drug Delivery for Trans-Arterial Chemoembolization (TACE) and Radioembolization (TARE),” was published online on April 9, 2026 in the Journal of Comparative Effectiveness Research. Using the Clarivate Real World Data Repository, researchers analyzed outcomes for 603 PEDD patients and 16,210 non-PEDD patients with hepatocellular carcinoma or secondary liver metastases who underwent TACE or TARE between January 2020 and March 2024. “This publication represents one of the largest and most comprehensive real-world analysis ever done in the interventional radiology space and reinforces what we’ve observed across clinical practice – that PEDD can improve outcomes for patients undergoing liver-directed therapies while also reducing the economic burden on the healthcare system,” said Dr. Richard Marshall, Chief Medical Officer at TriSalus Life Sciences.